Last checked at 28 Apr 2015 07:00
28 April 2015
Feedback plc
("Feedback" or the "Company")
Collaboration with the Princess Alexandra Hospital (PAH), Australia
Feedback plc (AIM: FDBK), the medical imaging software company, is pleased to announce that it is undertaking a study using its TexRAD research product with the Diagnostic Radiology department at the Princess Alexandra Hospital ("PAH") in Brisbane, Australia to assess the potential for clinical workflow integration for TexRAD quantitative computed tomography ("CT") specifically focused on non-small cell lung cancer.
The study will be led by Prof. Ken Miles (Senior Medical Officer in the Diagnostic Radiology department of PAH). Prof. Miles is also a Professorial Research Associate in the Institute of Nuclear Medicine, University College London, UK. Prof. Miles has an international reputation in functional imaging of tumours, ranging from the development of new techniques through to demonstrating cost-effectiveness. For example he has been one of the pioneers of CT perfusion (blood-flow) and CT texture (heterogeneity) analysis technologies.
Prof. Ken Miles commented:
"TexRAD as research software has been used to investigate lung cancer on CT where it has been shown to be associated with underlying tumour biology and has the potential to be an independent prognostic marker. Preliminary studies have also demonstrated potential clinical applications for TexRAD analysis to assist treatment decisions and optimise lung cancer patient management in a cost-effective manner. We hope this study will demonstrate that TexRAD could be incorporated into the routine radiological workflow."
Dr. Balaji Ganeshan, Chief Scientist & New Business Officer of the Company's subsidiaries TexRAD Ltd & Cambridge Computed Imaging Ltd commented:
"Prof. Ken Miles is one of the top functional imaging academics, dual trained in radiology and nuclear medicine and we are delighted that he will be leading the very first landmark study in evaluating potential clinical implementation with our TexRAD software focused on lung cancer. Working with Princess Alexandra Hospital in Brisbane will enhance our TexRAD research collaborator base with the addition of a key site in this new geographical region."
For further information contact:
Feedback plc | Tel: 01954 718072 |
Simon Barrell / Trevor Brown / Tom Charlton | |
Sanlam Securities UK (Nominated Adviser and Joint Broker) | Tel: 020 7628 2200 |
Simon Clements / Virginia Bull | |
Peterhouse Corporate Finance Ltd (Joint Broker) | Tel: 020 7469 0936 |
Lucy Williams / Duncan Vasey | |
Notes to editors:
TexRAD (is a novel sophisticated imaging risk stratification research tool that analyses the textures in existing radiological scans. This research software application analyses textures, detecting and measuring tumour heterogeneity (complexity) from these images, revealing more information from medical images than it is currently possible to see with the naked eye. Research to date has shown that TexRAD could potentially assist the clinician (as an 'Imaging-Biomarker') in confident decision-making: assessing the prognosis, disease-severity (e.g. risk of metastases) and response evaluation of patients with cancer. Currently TexRAD research has shown great potential in many different oncological sites, including, colorectal, breast, lung, prostate, oesophageal, head & neck, lymphoma, liver and renal cancers and could potentially be employed as a heterogeneity assessing tool in the era of 'Precision and Personalized Medicine'. TexRAD is manufactured under licence by the ISO 13485 certified company Cambridge Computed Imaging Ltd, a subsidiary of Feedback plc. More information is available on www.fbk.com and www.texrad.com.